Madrigal Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US5588681057

SecurityMDGL / Madrigal Pharmaceuticals, Inc.
InstitutionIFP Advisors, Inc
Latest Disclosed Ownership456 shares
Latest Disclosed Value $ 238,702
IFP Advisors, Inc reports 1.08% decrease in ownership of MDGL / Madrigal Pharmaceuticals, Inc.

On April 13, 2026 - IFP Advisors, Inc filed a 13F-HR form disclosing ownership of 456 shares of Madrigal Pharmaceuticals, Inc. (US:MDGL) valued at $238,702 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 461 shares of Madrigal Pharmaceuticals, Inc.. This represents a change in shares of -1.08% during the quarter. The current value of the position is $222,596 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-13 2026-03-31 13F MADRIGAL PHARMACEUTICALS cs 558868105 456 -5 -1.08 239 -11.19 0.0049
2026-02-06 2025-12-31 13F MADRIGAL PHARMACEUTICALS cs 558868105 461 90 24.26 268 57.65 0.0060
2026-02-06 2025-09-30 13F/A-1 MADRIGAL PHARMACEUTICALS INCCOM cs 558868105 371 19 5.40 170 46.55 0.0044
2025-12-02 2025-09-30 13F MADRIGAL PHARMACEUTICALS INCCOM cs 558868105 351 -1 179 0.0046
2025-07-24 2025-06-30 13F MADRIGAL PHARMACEUTICALS cs 558868105 352 -17 -4.61 117 -4.92 0.0033
2025-05-05 2025-03-31 13F MADRIGAL PHARMACEUTICALS cs 558868105 369 13 3.65 122 11.93 0.0038
2025-02-04 2024-12-31 13F MADRIGAL PHARMACEUTICALS cs 558868105 356 12 3.49 110 49.32 0.0036
2025-02-04 2024-09-30 13F MADRIGAL PHARMACEUTICALS cs 558868105 344 3 0.88 73 -23.16 0.0026
2024-07-30 2024-06-30 13F MADRIGAL PHARMACEUTICALS cs 558868105 341 341 96 0.0038
2021-10-06 2021-09-30 13F MADRIGAL PHARMACEUTICALS INC COM Stock 558868105 0 -1 -100.00 0 0.0000
2021-07-13 2021-06-30 13F MADRIGAL PHARMACEUTICALS INC COM Stock 558868105 1 1 0 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.